Research and Markets: The Treatment of Reno-Vascular Disease is Currently in a State of Evolution
August 12, 2005 (PRLEAP.COM) Health News
Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c22356) has announced the addition of Renal Artery Angioplasty & Stenting: Technology & Market Forecast to their offeringThe treatment of Reno-Vascular Disease is currently in a state of evolution. Current available endovascular devices allow almost all cases of Renal Artery Stenosis to be successfully opened.
The first successful balloon angioplasty of the Renal Artery was performed by Andreas Gruntzig in 1976 and over a decade of experience with Renal Artery Stenting (RAS) has demonstrated that stents can have the same benefits on acute revascularization of the Renal Arteries, as they do in virtually all other circulations.
The Renal Artery Angioplasty & Stenting - Technology & Market Forecast report gives an overview of the state of both the technology and the market. It profiles the current market landscape and explores the market potential with global forecasts to 2010.
The report details many pressing issues in the space including current approved and in-development devices and the impact of Drug Eluting Stents (DES), Vascular Brachytherapy and Embolic Protection Devices (EPDs).
With Renal Artery Angioplasty & Stenting - Technology & Market Forecast you will be better able to:
- Understand current market dynamics, competitors positions and market shares
- Identify emerging technologies and the companies behind them
- Leverage your own technology and brain storm new business opportunities
- Assess market size and growth potential
- Monitor the competition's marketed and in-development products
- Investigate mergers, acquisitions and licensing possibilities
- Assess market potential and have access to forecasts till 2010
Renal Artery Angioplasty & Stenting - Technology & Market Forecast gives a short but thorough analysis of the current situation and growth trends of the global market for these devices. It is targeted at busy medtech executives & venture capitalists scanning for windows of opportunities opening in the endovascular space.
For more information visit http://www.researchandmarkets.com/reports/c22356
Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980